Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
Table of Contents

 
OREXIGEN THERAPEUTICS, INC.
(a development stage company)

STATEMENTS OF OPERATIONS
 
                                 
                      Period from
 
                      September 12, 2002
 
                      (Inception) to
 
    Years Ended December 31,     December 31,
 
    2004     2005     2006     2006  
 
Revenues:
                               
Collaborative agreement
  $     $ 174,137     $     $ 174,137  
License revenue
          88,230       88,239       176,469  
                                 
Total revenues
          262,367       88,239       350,606  
Operating expenses:
                               
Research and development
    6,144,510       9,708,935       22,586,151       39,603,549  
General and administrative
    1,590,500       3,386,167       5,869,438       11,514,493  
                                 
Total operating expenses
    7,735,010       13,095,102       28,455,589       51,118,042  
                                 
Loss from operations
    (7,735,010 )     (12,832,735 )     (28,367,350 )     (50,767,436 )
Other income (expense):
                               
Interest income
    47,376       744,165       871,904       1,663,445  
Interest expense
    (5,702 )           (8,266 )     (64,013 )
                                 
Net loss
    (7,693,336 )     (12,088,570 )     (27,503,712 )     (49,168,004 )
Accretion to redemption value of redeemable convertible preferred stock
    (12,920 )     (24,142 )     (30,538 )     (67,600 )
                                 
Deemed dividend of beneficial conversion for Series C preferred stock
                (13,859,649 )     (13,859,649 )
                                 
Net loss attributable to common stockholders
  $ (7,706,256 )   $ (12,112,712 )   $ (41,393,899 )   $ (63,095,253 )
                                 
Net loss per share attributable to common stockholders — basic and diluted
  $ (5.01 )   $ (6.12 )   $ (18.87 )        
                                 
Shares used to compute basic and diluted net loss per share attributable to common stockholders
    1,538,628       1,980,253       2,193,068          
                                 
Pro forma basic and diluted net loss per share attributable to common stockholders (unaudited)
                  $ (1.87 )        
                                 
Shares used to compute pro forma basic and diluted net loss per share attributable to common stockholders (unaudited)
                    14,737,974          
                                 
 
See accompanying notes.


F-4